Geared toward ambulatory use, the HeartKey Rhythm suite reportedly offers enhanced signal clarity and rhythm detection algorithms.
While noise contamination has been an issue with electrocardiograms (ECGs), a newly FDA-cleared suite of ECG algorithms may bolster signal clarity and detection of cardiac conditions.
Featuring unique signal processing technology, the HeartKey Rhythm suite facilitates noise reduction and improved data quality with ECGs, according to B-Secur, the developer of HeartKey Rhythm.1 The company maintains that the HeartKey Rhythm suite provides an antidote for challenges with ECG interpretation, citing a 2020 survey in which 53 percent of clinicians noted difficulty with interpreting remote ECGs.2
"There is an ever-increasing reliance on ECG data collected outside of a controlled clinical environment," said Adrian Condon, the chief technology officer and co-founder of B-Secur. "Our breakthrough FDA cleared product, HeartKey Rhythm, significantly improves the ECG signal processing and rhythm recognition of ambulatory devices and platforms."
The company added that on-chip solutions with the HeartKey Rhythm suite can be utilized for patient wearable devices, further facilitating timely care for common cardiac conditions.
References
1. B-Secur. B-Secur elevates proactive, efficient cardiac care with FSA-cleared HeartKey Rhythm solution. PR Newswire. Available at: https://www.prnewswire.com/news-releases/b-secur-elevates-proactive-efficient-cardiac-care-with-fda-cleared-heartkey-rhythm-solution-302236210.html?tc=eml_cleartime . Published September 3, 2024. Accessed September 5, 2024.
2. Ding EY, Svennberg E, Wurster C, et al. Survey of current perspectives on consumer-available digital health devices for detecting atrial fibrillation. Cardiovasc Digit Health J. 2020;1(1):21-29.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
What a Prospective CT Study Reveals About Adjunctive AI for Triage of Intracranial Hemorrhages
September 4th 2024Adjunctive AI showed no difference in accuracy than unassisted radiologists for intracranial hemorrhage (ICH) detection and had a slightly longer mean report turnaround time for ICH-positive cases, according to newly published prospective research.